Suppr超能文献

载药微球经导管栓塞治疗:猪体内药物渗透和覆盖的实验研究。

Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine.

机构信息

Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10 Room 1C341 MSC 1182, Bethesda, MD 20892, USA.

出版信息

J Vasc Interv Radiol. 2012 Feb;23(2):257-64.e4. doi: 10.1016/j.jvir.2011.10.019. Epub 2011 Dec 16.

Abstract

PURPOSE

To determine local doxorubicin levels surrounding radiopaque drug-eluting beads (DEBs) in normal swine liver and kidney following transcatheter arterial chemoembolization. The influence of bead size (70-150 μm or 100-300 μm) was compared with regard to tissue penetration and spatial distribution of the bead, as well as eventual drug coverage (ie, amount of tissue exposed to drug).

MATERIALS AND METHODS

Radiopaque DEBs were synthesized by suspension polymerization followed by incorporation of iodized oil and doxorubicin. Chemoembolization of swine liver and kidney was performed under fluoroscopic guidance. Three-dimensional tissue penetration of "imageable" DEBs was investigated ex vivo with micro-computed tomography (microCT). Drug penetration from the bead surface and drug coverage was evaluated with epifluorescence microscopy, and cellular localization of doxorubicin was evaluated with confocal microscopy. Necrosis was evaluated with hematoxylin and eosin staining.

RESULTS

MicroCT demonstrated that 70-150-μm DEBs were present in more distal arteries and located in a more frequent and homogeneous spatial distribution. Tissue penetration of doxorubicin from the bead appeared similar (∼300 μm) for both DEBs, with a maximum tissue drug concentration at 1 hour coinciding with nuclear localization of doxorubicin. The greater spatial frequency of the 70-150-μm DEBs resulted in approximately twofold improved drug coverage in kidney. Cellular death is predominantly observed around the DEBs beginning at 8 hours, but increased at 24 and 168 hours.

CONCLUSIONS

Smaller DEBs penetrated further into targeted tissue (ie, macroscopic) with a higher spatial density, resulting in greater and more uniform drug coverage (ie, microscopic) in swine.

摘要

目的

经导管动脉化疗栓塞后,在正常猪的肝、肾中确定放射性不透射线的载药微球(DEB)周围的局部阿霉素水平。比较了微球粒径(70-150μm 或 100-300μm)对组织穿透性和微球空间分布的影响,以及最终的药物覆盖范围(即暴露于药物的组织量)。

材料和方法

通过悬浮聚合合成放射性不透射线的 DEB,然后掺入碘化油和阿霉素。在透视引导下对猪的肝、肾进行化疗栓塞。用微计算机断层扫描(microCT)体外研究“可成像”DEB 的三维组织穿透性。用荧光显微镜评估从微球表面的药物穿透和药物覆盖范围,并通过共聚焦显微镜评估阿霉素的细胞定位。用苏木精-伊红染色评估坏死。

结果

microCT 显示,70-150μm 的 DEB 存在于更远端的动脉中,并且分布更频繁且均匀。两种 DEB 的药物从微球表面的穿透性似乎相似(约 300μm),1 小时时的最大组织药物浓度与阿霉素的核定位一致。70-150μm 的 DEB 更大的空间频率导致肾内药物覆盖范围增加约两倍。从 8 小时开始,主要观察到 DEB 周围的细胞死亡增加,而在 24 小时和 168 小时时则增加更多。

结论

较小的 DEB 更深入地穿透靶向组织(即宏观),具有更高的空间密度,从而导致在猪中更大且更均匀的药物覆盖范围(即微观)。

相似文献

1
Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine.
J Vasc Interv Radiol. 2012 Feb;23(2):257-64.e4. doi: 10.1016/j.jvir.2011.10.019. Epub 2011 Dec 16.
2
Preparation of Radiopaque Drug-Eluting Beads for Transcatheter Chemoembolization.
J Vasc Interv Radiol. 2016 Jan;27(1):117-126.e3. doi: 10.1016/j.jvir.2015.09.011. Epub 2015 Nov 6.
5
Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model.
J Vasc Interv Radiol. 2010 Feb;21(2):259-67. doi: 10.1016/j.jvir.2009.10.026.
6
Development of "imageable" beads for transcatheter embolotherapy.
J Vasc Interv Radiol. 2010 Jun;21(6):865-76. doi: 10.1016/j.jvir.2010.02.031.
7
In situ evaluation of spatiotemporal distribution of doxorubicin from Drug-eluting Beads in a tissue mimicking phantom.
Eur J Pharm Sci. 2021 May 1;160:105772. doi: 10.1016/j.ejps.2021.105772. Epub 2021 Feb 20.
10
DC BeadM1™: towards an optimal transcatheter hepatic tumour therapy.
J Mater Sci Mater Med. 2016 Jan;27(1):13. doi: 10.1007/s10856-015-5629-6. Epub 2015 Dec 16.

引用本文的文献

1
Design and optimization of imageable microspheres for locoregional cancer therapy.
Sci Rep. 2025 Jul 28;15(1):27487. doi: 10.1038/s41598-025-12182-5.
4
Embolic Agents: Particles.
Semin Intervent Radiol. 2023 Jul 20;40(3):315-322. doi: 10.1055/s-0043-1769744. eCollection 2023 Jun.
5
Microfluidic fabrication of X-ray-visible sodium hyaluronate microspheres for embolization.
RSC Adv. 2023 Jul 10;13(30):20512-20519. doi: 10.1039/d3ra02812g. eCollection 2023 Jul 7.
6
Prospective Series of Transarterial Chemoembolization of Metastatic Colorectal Cancer to the Liver with 30-60 μm Microspheres Loaded with Irinotecan.
Cardiovasc Intervent Radiol. 2023 Jul;46(7):880-890. doi: 10.1007/s00270-023-03446-6. Epub 2023 Jun 19.
7
Bench-to-bedside development of multifunctional flexible embolic agents.
Theranostics. 2023 Apr 1;13(7):2114-2139. doi: 10.7150/thno.80213. eCollection 2023.
9
A 3D Tumor-Mimicking In Vitro Drug Release Model of Locoregional Chemoembolization Using Deep Learning-Based Quantitative Analyses.
Adv Sci (Weinh). 2023 Apr;10(11):e2206195. doi: 10.1002/advs.202206195. Epub 2023 Feb 15.

本文引用的文献

3
First multimodal embolization particles visible on x-ray/computed tomography and magnetic resonance imaging.
Invest Radiol. 2011 Mar;46(3):178-86. doi: 10.1097/RLI.0b013e318205af53.
4
Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization?
Cardiovasc Intervent Radiol. 2011 Feb;34(1):37-49. doi: 10.1007/s00270-010-0012-y. Epub 2010 Nov 12.
5
Development of "imageable" beads for transcatheter embolotherapy.
J Vasc Interv Radiol. 2010 Jun;21(6):865-76. doi: 10.1016/j.jvir.2010.02.031.
6
Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies.
Cancer J. 2010 Mar-Apr;16(2):163-75. doi: 10.1097/PPO.0b013e3181d7e8cf.
8
Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model.
J Vasc Interv Radiol. 2010 Feb;21(2):259-67. doi: 10.1016/j.jvir.2009.10.026.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验